Abstract 1199P
Background
Homologous recombination repair (HRR) genes play a critical role in tumor DNA damage repair. Loss-of function HRR alternation, including SNV/Indel and homozygous deletion (HD), could predict sensitivity of poly ADP-ribose polymerase (PARP) inhibitor. Therefore, developing a comprehensive and reliable HRR detection approach is necessary.
Methods
In this study, prostate samples (cancer tissue specimens and cell lines) carrying HRR SNV/Indel/HD alterations or wild-type genomes were used to assess the performance of a Next Generation Sequencing (NGS) kit (AmoyDx HRD Complete Panel) for the SNV/Indel/HD detection, which covers 17 HRR genes and 3 tumor-associated genes. The AmoyDx master panel was used as a reference test.
Results
Of the 102 prostate cancer samples (including 19 BRCA1/2 SNV/indel-positive samples and 1 BRCA2 HD-positive sample), positive percent agreement (PPA), negative percent agreement (NPA), and overall percent agreement (OPA) of the two NGS kits for BRCA1/2 detection were all 100%. 8 SNV/Indel-positive samples were constructed into 576 reactions that were validated by gradient dilution and repetition. The limit of detection (LOD) criterion for SNV/Indel were ≥ 5% and the amount of DNA input was 30 ng. Detection sensitivity for HD at the exon level was 100% when tumor purity was greater than 40% and DNA input was 100ng. For gene level HD, tumor purity ≥ 30% was required. 8 SNV/Indel/HD positive or negative (4 SVN/Indel positive, 2 HD positive, 2 SNV/Indel/HD negative) samples were tested repeatedly with different batches of reagents in different time periods. The coefficient of variance (CV) of positive samples was less than 10%, and the negative samples were all negative for repeat testing. In the presence of hemoglobin, triglyceride, and paclitaxel during the extraction process, or ethanol (found in DNA samples), xylene, or proteinase K during the DNA addition, the OPA of testing samples was 100% compared to the reference.
Conclusions
This study demonstrated that Amoydx human homologous recombination repair gene panel exhibited high concordance with AmoyDx master panel and could provide reliable HRR SNV/Indel/HD detection.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
X. Lin, Y. Guo, P. Cheng, Z. Huang, C. Zhu: Financial Interests, Institutional, Full or part-time Employment: Amoy Diagnostics Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
1607P - Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 10
1608P - Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial
Presenter: Michael Hofman
Session: Poster session 10
1609P - PSMA-PET and PROMISE re-define stage and risk in patients with prostate cancer
Presenter: Wolfgang Fendler
Session: Poster session 10
1610P - Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig
Presenter: Andrew Armstrong
Session: Poster session 10
1611P - Haematologic impact of [177Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore
Presenter: Kim Nguyen Chi
Session: Poster session 10
1612P - Impact of FANCA, ATM, CDK12 alterations on survival in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: David Lorente
Session: Poster session 10
1613P - Clinically advanced prostate cancer (CAPC) featuring BRCA2 loss: A comprehensive genomic profiling (CGP) study
Presenter: Chiara Mercinelli
Session: Poster session 10
1614P - PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT)
Presenter: Ravi Madan
Session: Poster session 10
1615P - A new prognostic model of overall survival (OS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC)
Presenter: Susan Halabi
Session: Poster session 10